MPLT:NASDAQMapLight Therapeutics, Inc. Analysis

MapLight Therapeutics (MPLT) is trading at $28.61, just above the computed support of $25.21 and well below the recent high of $31.25, suggesting limited upside in the immediate term. Technical indicators show a bullish trend direction with the 20‑day SMA (≈28.76) above the 50‑day SMA (≈28.51) and both above the 200‑day SMA (≈20.94), while the RSI sits near the midpoint at 49.8, indicating no strong overbought or oversold pressure. However, the MACD histogram is negative and the signal line is labeled bearish, hinting at short‑term momentum weakness. The stock exhibits very high 30‑day volatility (≈77.6%) and a beta of 1.56, amplifying price swings in the current “Extreme Greed” market sentiment (Fear‑Greed Index 88.77).
On the fundamental side, MPLT remains pre‑revenue with negative earnings (trailing EPS –$4.41) and a forward P/E of –6.68, but it holds $311 M in cash against modest debt, yielding a price‑to‑book of 3.23. Recent material news includes completion of enrollment in the ZEPHYR Phase 2 schizophrenia trial and the IRIS Phase 2 autism trial, with topline results expected by mid‑August 2026. Analyst coverage from UBS and Craig‑Hallum has upgraded the stock to a Buy with median price targets around $36.5, implying roughly 35% upside, while insider sales have been modest and do not appear to signal a loss of confidence.